Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients Clinical research trials and Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients. Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients clinical trial. Human subjects often get the best healthcare available for their Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "F" Clinical Trials Conditions > Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients



Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

For Condition: HIV Infections
Status: Completed
Sponsor(s): Louisiana State University ,
Synopsis: To determine if Thalidomide modulates the production of HIV-suppressor factors (MIP-1 alpha, MIP-1 beta, Rantes) and TH1 type cytokines (IL-12 and INF-gamma) in HIV-infected patients and alters viral load.
Details: Patients will be divided, 5 per group, into Groups I, II, III and IV. Groups I and II will include patients who have decided not to take anti-retro viral drugs. Groups III and IV will include patients receiving the same types of antiretroviral drugs. Patients in groups I and III will receive thalidomide while patients in group II and IV will receive placebo. The placebo capsules will be the same color as the thalidomide capsules and will contain glucose powder. Patients will ingest one capsule of thalidomide at 9 PM daily on days 0, 1, 2, 3, 4, 5 and 6.
Eligibility:
Study Type:  Interventional, Treatment, Double-Blind
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV infection. - CD4+ cell count >= 200/microliter or > 14% CD4+ cells in peripheral blood. - Willingness to commit to the study duration and agree to abide to the time table for entry into the study, ingestion of thalidomide and follow-up. Exclusion Criteria Co-existing Condition: Patients with any of the following conditions or symptoms are excluded: - Fertile females. - Patients who participated in a clinical study involving a new drug or device within the last 2 months or the period of time equivalent to seven times the half life of the study drug, whichever is longer. Patients with any of the following prior conditions are excluded: HIV related pre-existing peripheral neuropathy. Prior Medication: Excluded: Patients using systemic steroidal anti inflammatory drugs or pentoxifylline within 10 days of dosing with thalidomide. Required: 10 of the 20 patients must be on antiretroviral therapy and the other 10 will be subjects who have decided not to be on any antiretroviral drug prior to enrollment into this study and do not plan to start such treatment during the study period.
Total Enrollment: 20

Location and Contact Information:

Ochsner Clinic
New Orleans,  Louisiana,  70102
United States
 


Additional Information:
Study ID Numbers:  262A; 
Study Start Date: 
Record last reviewed: July 1997
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002174

Other Hiv Infections Studies:
1. A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients with CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy

2. Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection

3. A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma

4. Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex

5. Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

Related Studies:

Other HIV Infections Clinical Trials
Other Louisiana Clinical Trials
Other New Orleans Clinical Trials

Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients
Modify your Search

  Other HIV Infections Clinical Trials
  Other Louisiana Clinical Trials
  Other New Orleans Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103